← Back to Search

Mobile Gaming App for PrEP Adherence

N/A
Waitlist Available
Research Sponsored by Rhode Island Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a mobile game (Viral Combat) to see if it helps people ages 15-34 taking PrEP care in the South and New England. Interviews will inform game adaptations and a Hybrid Type 1 RCT will test its efficacy. A summative evaluation will help with future implementation and dissemination.

Who is the study for?
This trial is for English-speaking individuals aged 15-34 who have recently started or restarted PrEP (a medication to prevent HIV) within the last month, are HIV negative, and can consent to participate. There are no specific exclusion criteria.
What is being tested?
The study is testing 'Viral Combat,' a mobile game designed to improve adherence to PrEP among young people in clinical settings across New England and Mississippi. It's compared with a control group using a non-PrEP related game through a randomized controlled trial.
What are the potential side effects?
Since this trial involves the use of a gaming app rather than medication, traditional side effects aren't applicable. However, participants may experience issues typical of mobile gaming like eye strain or repetitive stress injuries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Tenofovir (TFV) blood concentration at 24 weeks
Secondary study objectives
Medical appointment adherence at 24 weeks
Medical appointment adherence at 48 weeks
Self-reported Medication Adherence at 24 weeks
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Multilevel Gaming AdherenceExperimental Treatment1 Intervention
Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Viral Combat on their mobile phones, and, for 24 weeks, game-related text messages guided by self-reported medication adherence.
Group II: Treatment as Usual +Active Control1 Intervention
TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game.

Find a Location

Who is running the clinical trial?

Rhode Island HospitalLead Sponsor
264 Previous Clinical Trials
68,579 Total Patients Enrolled
Larry K Brock, MDStudy DirectorRhode Island Hospital
Sharon Vuppula, MDStudy DirectorBoston Medical Center

Media Library

Multilevel Gaming Adherence Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05762705 — N/A
Medication Adherence Research Study Groups: Multilevel Gaming Adherence, Treatment as Usual +
Medication Adherence Clinical Trial 2023: Multilevel Gaming Adherence Intervention Highlights & Side Effects. Trial Name: NCT05762705 — N/A
Multilevel Gaming Adherence Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05762705 — N/A
~133 spots leftby Aug 2026